Pharmaxis completes enrollment in Aridol pulmonary disease trial

By Elaine Rigoli

Tampa, Fla., April 11 - Pharmaxis Ltd. announced Tuesday that it has completed enrollment in its clinical trial to test Aridol's ability to predict response to treatment in patients with chronic obstructive pulmonary disease.

The trial began in September 2005, and is being conducted at 11 hospitals in five states across Australia, according to a company news release.

Patients who volunteer for the trial receive an Aridol test followed by 12 weeks of treatment with an inhaled steroid to control lung inflammation.

The trial will record differences in lung function, quality of life and the general health of the patient.

Data from the study is expected to be available by September 2006, the release said.

Sydney, Australia-based Pharmaxis is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.